Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Must have received: systemic chemotherapy

at least 1 but no more than 2 prior lines of systemic treatment with a preferred first line chemotherapy regimens

Must have received: systemic therapy

at least 2 but no more than 3 prior lines of systemic therapy

Cannot have received: DR5 agonist

Prior treatment with or exposure to DR5 agonists

Cannot have received: anticancer therapy (including investigational agents)

Exception: Exceptions per protocol

Receipt of any anticancer therapy (including investigational agents) within 4 weeks or within 5 half-lives prior to the first dose of study treatment

Cannot have received: radiotherapy

Receipt of radiotherapy within 4 weeks prior to the first dose of study treatment, and liver-directed within 12 months prior to the first dose of study drug

Cannot have received: allogeneic hematopoietic stem cell or bone marrow transplantation

Exception: Exceptions per protocol

Subject has undergone allogeneic hematopoietic stem cell or bone marrow transplantation within the last 5 years